Lee, Wan-HungXu, ZhiliAshpole, Nicole M.Hudmon, AndyKulkarni, Pushkar M.Thakur, Ganesh A.Lai, Yvonne Y.Hohmann, Andrea G.2016-12-082016-12-082015-10Lee, W.-H., Xu, Z., Ashpole, N. M., Hudmon, A., Kulkarni, P. M., Thakur, G. A., … Hohmann, A. G. (2015). Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology, 97, 464–475. https://doi.org/10.1016/j.neuropharm.2015.05.0380028-3908 1873-7064https://hdl.handle.net/1805/11575Aberrant increases in NMDA receptor (NMDAR) signaling contributes to central nervous system sensitization and chronic pain by activating neuronal nitric oxide synthase (nNOS) and generating nitric oxide (NO). Because the scaffolding protein postsynaptic density 95kDA (PSD95) tethers nNOS to NMDARs, the PSD95-nNOS complex represents a therapeutic target. Small molecule inhibitors IC87201 (EC5O: 23.94 µM) and ZL006 (EC50: 12.88 µM) directly inhibited binding of purified PSD95 and nNOS proteins in AlphaScreen without altering binding of PSD95 to ErbB4. Bothen-USPublisher PolicyAllodyniaCentral sensitizationComplete Freund's adjuvantNMDARNeuronal nitric oxide synthaseNeuropathic painPostsynaptic density 95motor ataxiapaclitaxelArticle